Legend Biotech Analyst Ratings
RBC Capital Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $86
Analysts Are Bullish on These Healthcare Stocks: Entera Bio (ENTX), Legend Biotech (LEGN)
Legend Biotech Analyst Ratings
H.C. Wainwright Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $73
Truist Financial Maintains Legend Biotech(LEGN.US) With Buy Rating
Legend Biotech Price Target Maintained With a $86.00/Share by RBC Capital
Legend Biotech Analyst Ratings
Strong Market Acceptance and Strategic Growth Potential Justify Buy Rating for Legend Biotech
Barclays Sticks to Their Buy Rating for Legend Biotech (LEGN)
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Staar Surgical (STAA) and Organon (OGN)
Legend Biotech (LEGN) Gets a Hold From William Blair
Scotiabank Sticks to Their Buy Rating for Legend Biotech (LEGN)
Buy Rating on Legend Biotech: Strong Carvykti Sales and High Market Potential Signal Upside
Legend Biotech Analyst Ratings
The Latest Analyst Ratings For Legend Biotech
TD Cowen Adjusts Legend Biotech Price Target to $67 From $71, Maintains Buy Rating
Legend Biotech Analyst Ratings
Truist Financial Remains a Buy on Legend Biotech (LEGN)
Analysts Offer Insights on Healthcare Companies: R1 RCM (RCM), Legend Biotech (LEGN) and Intuitive Surgical (ISRG)